Why Xeltis Just Raised $21.6M to Make Body-Grown Blood Vessels a Reality

Jan de Vries · 2026-07-28

### The Big Picture: A MedTech Breakthrough for Dialysis Patients Xeltis, a Dutch-American company, just pulled in another $21.6 million to push its game-changing tech forward. They make artificial blood vessels that slowly turn into your own living tissue. Think of it like a scaffold that your body naturally replaces over time. This round was led by new investor Horizon 3 Healthcare, with help from the European Innovation Council, Invest-NL, and others. The money will fund their U.S. clinical trial for aXess, their lead product, and ramp up commercial sales in Europe. ### How It Works: Your Body Does the Heavy Lifting Xeltis uses a platform called Restorex. It's a polymer implant that acts as a temporary structure. Your body's cells move in, build new tissue, and the polymer dissolves. What's left is a living, breathing blood vessel made from your own cells. This is a huge deal for hemodialysis patients who need reliable vascular access. Current options often fail over time, requiring repeat surgeries. Xeltis aims to change that. ### What They're Funding Right Now The company has three main programs moving forward: - **aXess** – Their lead product for hemodialysis access, already approved in Europe (CE Mark) and now enrolling patients in a U.S. pivotal trial (over 50% enrolled). - **XABG** – A coronary artery bypass graft program. - **XPAD** – A peripheral artery disease program. All three use the same Restorex platform, so progress in one area helps the others. ### The Numbers Behind the Hype This isn't Xeltis's first big raise. In 2025, they secured $54 million from the European Investment Bank and existing shareholders. Add in $16.2 million from Chinese firm Grand Pharma in 2022, and you get a company that's been building momentum for years. CEO Eliane Schutte says the new funding will help them finish the U.S. trial, prepare for FDA submission, and scale manufacturing. They already treated their first commercial patient in Germany, so the European rollout is underway. ### Why Investors Are Betting Big Matt McNamara from Horizon 3 Healthcare put it plainly: "The data generated by Xeltis to date has been highly compelling." When a VC firm that specializes in healthcare says that, you pay attention. The market need is massive. Millions of patients need hemodialysis access or cardiovascular replacements every year. Current solutions often fail, leading to repeat procedures and worse outcomes. Xeltis offers a one-and-done approach that could save healthcare systems money and patients pain. ### What This Means for the Industry If Xeltis succeeds, it could reshape how we think about implants. Instead of permanent foreign objects, we'd have temporary scaffolds that become part of the body. That's a paradigm shift. The company's pipeline also has potential beyond dialysis. Heart bypass grafts, peripheral artery disease treatments, and more could all benefit from the same technology. That's why investors keep writing checks. ### The Road Ahead Xeltis has a clear path: finish the U.S. trial, get FDA approval, launch in America, and keep expanding in Europe. They're also advancing their other programs in the clinic. For U.S. professionals watching European MedTech, this is one to track. The science is solid, the funding is there, and the market need is real. If they execute, Xeltis could become a household name in vascular access.